<p>Corcept Therapeutics（纳斯达克代码：CORT - 获取免费报告）在周五发布的研究报告中，由 Canaccord Genuity Group 的股票分析师将其目标价格从 142.00 美元下调至 137.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。Canaccord Genuity Group 的目标价格意味着该股票当前价格有 98.57% 的潜在上涨空间。</p>
<ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
<p>其他一些研究分析师最近也对 CORT 发布了报告。Truist Financial 在 5 月 6 日的研究报告中将 Corcept Therapeutics 的目标价格设定为 135.00 美元。HC Wainwright 将 Corcept Therapeutics 的目标价格从 150.00 美元下调至 145.00 美元，并在 5 月 6 日的研究报告中对该股票给予 “买入” 评级。Piper Sandler 在周五的研究报告中将 Corcept Therapeutics 的目标价格从 131.00 美元下调至 121.00 美元，并对该股票给予 “增持” 评级。最后，Wall Street Zen 在 5 月 14 日的研究报告中将 Corcept Therapeutics 的评级从 “买入” 下调至 “持有”。一位分析师对该股票给予 “持有” 评级，五位分析师给予 “买入” 评级。根据 MarketBeat 的数据，Corcept Therapeutics 的共识评级为 “适度买入”，平均目标价格为 134.50 美元。</p>
<p>获取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们关于 CORT 的最新报告</strong></p>
<h2>Corcept Therapeutics 价格表现</h2>
<p>周五，CORT 股票在交易时段上涨 1.82 美元，达到 68.99 美元。该股票的交易量为 645,560 股，而其平均交易量为 1,366,292 股。该公司的市值为 73.2 亿美元，市盈率为 59.15，贝塔值为 0.15。该公司有 50 日简单移动平均线为 71.81 美元，200 日简单移动平均线为 68.21 美元。Corcept Therapeutics 的 12 个月最低价为 32.33 美元，最高价为 117.33 美元。</p>
<p>Corcept Therapeutics（纳斯达克代码：CORT - 获取免费报告）最近于 7 月 31 日发布了季度财报。这家生物技术公司报告本季度每股收益为 0.29 美元，超出分析师共识预期的 0.23 美元，超出幅度为 0.06 美元。Corcept Therapeutics 的净利润率为 19.33%，股本回报率为 20.40%。该公司本季度的收入为 1.9443 亿美元，而分析师预期为 1.9940 亿美元。去年同期，该公司每股收益为 0.32 美元。与去年同期相比，该公司的季度收入增长了 18.7%。平均而言，股票分析师预计 Corcept Therapeutics 今年将发布 1.36 美元的每股收益。</p>
<h2>内部买卖</h2>
<p>在其他新闻中，首席执行官 Joseph K. Belanoff 于 7 月 17 日出售了 615 股公司的股票，交易发生在该日。股票以平均价格 73.69 美元出售，总价值为 45,319.35 美元。出售后，首席执行官直接持有该公司 2,901,370 股股票，估值约为 213,801,955.30 美元。这笔交易代表其持股比例下降了 0.02%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，内部人士 Sean Maduck 于 7 月 18 日出售了 473 股公司的股票，交易发生在该日。股票以平均价格 73.44 美元出售，总交易额为 34,737.12 美元。交易完成后，该内部人士持有 17,705 股公司股票，估值约为 1,300,255.20 美元。这笔交易代表其持股比例下降了 2.60%。该销售的披露信息可以在这里找到。内部人士在上个季度总共出售了价值 13,237,621 美元的 173,038 股公司股票。公司内部人士持有该公司 20.80% 的股份。</p>
<h2>机构资金流入和流出</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Brooklyn Investment Group 在第一季度将其在 Corcept Therapeutics 的股份增加了 99.5%。Brooklyn Investment Group 现在拥有 373 股生物技术公司的股票，估值为 43,000 美元，此前在上个季度又增持了 186 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在 Corcept Therapeutics 的股份增加了 102.0%。MassMutual Private Wealth &amp; Trust FSB 现在拥有 620 股生物技术公司的股票，估值为 71,000 美元，此前在上个季度又增持了 313 股。Covestor Ltd 在第一季度将其在 Corcept Therapeutics 的持股增加了 1,741.2%。Covestor Ltd 现在拥有 626 股生物技术公司的股票，价值 72,000 美元，此前在上个季度又增持了 592 股。IFP Advisors Inc 在第一季度将其在 Corcept Therapeutics 的持股增加了 1,150.8%。IFP Advisors Inc 现在拥有 738 股生物技术公司的股票，价值 84,000 美元，此前在上个季度又增持了 679 股。最后，USA Financial Formulas 在第二季度购买了 Corcept Therapeutics 的新股份，价值约为 56,000 美元。机构投资者持有该公司 93.61% 的股份。</p>
<h2>Corcept Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Corcept Therapeutics Incorporated 在美国从事用于治疗严重内分泌、肿瘤、代谢和神经系统疾病的药物的发现和开发。它提供 Korlym 片剂，用于治疗因内源性库欣综合症导致的高血糖症，适用于成年患者；以及患有 2 型糖尿病或葡萄糖耐受不良且未能接受手术或不适合手术的患者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而非 Corcept Therapeutics</li>
<li>现在可以购买的两只金融科技股票和一只需要避免的股票</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>零售投资者如何交易多伦多证券交易所 (TSX)？</li>
<li>苹果股票：大盈利，小波动——是时候购买了吗？</li>
<li>便士股票适合你的投资组合吗？</li>
<li>亚马逊的盈利：接下来会发生什么以及如何应对</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Corcept Therapeutics 吗？</h2>
<p>在考虑 Corcept Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Corcept Therapeutics 并不在名单上。</p>
<p>虽然 Corcept Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Corcept医疗

<p>Canaccord Genuity Group 已将 Corcept Therapeutics（NASDAQ:CORT）的目标股价从 142.00 美元下调至 137.00 美元，同时维持 “买入” 评级。这个新目标暗示从当前股价来看，潜在上涨幅度为 98.57%。其他分析师也调整了他们的目标股价，普遍评级为 “适度买入”，平均目标价为 134.50 美元。Corcept 的股票最近交易价格为 68.99 美元，市值为 73.2 亿美元，市盈率为 59.15</p>

<p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) had its price objective cut by stock analysts at Canaccord Genuity Group from $142.00 to $137.00 in a research note issued on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. Canaccord Genuity Group's target price would indicate a potential upside of 98.57% from the stock's current price.</p>
<div class="lb-trans"><p>Corcept Therapeutics（纳斯达克代码：CORT - 获取免费报告）在周五发布的研究报告中，由 Canaccord Genuity Group 的股票分析师将其目标价格从 142.00 美元下调至 137.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。Canaccord Genuity Group 的目标价格意味着该股票当前价格有 98.57% 的潜在上涨空间。</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆势而上的生物制药股票</li>
</ul>
</div><p>A number of other research analysts also recently issued reports on CORT. Truist Financial set a $135.00 target price on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. HC Wainwright cut their target price on shares of Corcept Therapeutics from $150.00 to $145.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, May 6th. Piper Sandler cut their target price on shares of Corcept Therapeutics from $131.00 to $121.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday. Finally, Wall Street Zen cut shares of Corcept Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, Corcept Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $134.50.</p>
<div class="lb-trans"><p>其他一些研究分析师最近也对 CORT 发布了报告。Truist Financial 在 5 月 6 日的研究报告中将 Corcept Therapeutics 的目标价格设定为 135.00 美元。HC Wainwright 将 Corcept Therapeutics 的目标价格从 150.00 美元下调至 145.00 美元，并在 5 月 6 日的研究报告中对该股票给予 “买入” 评级。Piper Sandler 在周五的研究报告中将 Corcept Therapeutics 的目标价格从 131.00 美元下调至 121.00 美元，并对该股票给予 “增持” 评级。最后，Wall Street Zen 在 5 月 14 日的研究报告中将 Corcept Therapeutics 的评级从 “买入” 下调至 “持有”。一位分析师对该股票给予 “持有” 评级，五位分析师给予 “买入” 评级。根据 MarketBeat 的数据，Corcept Therapeutics 的共识评级为 “适度买入”，平均目标价格为 134.50 美元。</p>
</div><p>Get <strong>Corcept Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corcept Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Report on CORT</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CORT 的最新报告</strong></p>
</div><h2>Corcept Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 价格表现</h2>
</div><p>Shares of CORT stock traded up $1.82 during trading hours on Friday, reaching $68.99. The stock had a trading volume of 645,560 shares, compared to its average volume of 1,366,292. The firm has a market capitalization of $7.32 billion, a PE ratio of 59.15 and a beta of 0.15. The firm has a 50-day simple moving average of $71.81 and a 200-day simple moving average of $68.21. Corcept Therapeutics has a twelve month low of $32.33 and a twelve month high of $117.33.</p>
<div class="lb-trans"><p>周五，CORT 股票在交易时段上涨 1.82 美元，达到 68.99 美元。该股票的交易量为 645,560 股，而其平均交易量为 1,366,292 股。该公司的市值为 73.2 亿美元，市盈率为 59.15，贝塔值为 0.15。该公司有 50 日简单移动平均线为 71.81 美元，200 日简单移动平均线为 68.21 美元。Corcept Therapeutics 的 12 个月最低价为 32.33 美元，最高价为 117.33 美元。</p>
</div><p>Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a net margin of 19.33% and a return on equity of 20.40%. The company had revenue of $194.43 million for the quarter, compared to analyst estimates of $199.40 million. During the same quarter last year, the firm posted $0.32 earnings per share. The company's quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities analysts anticipate that Corcept Therapeutics will post 1.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corcept Therapeutics（纳斯达克代码：CORT - 获取免费报告）最近于 7 月 31 日发布了季度财报。这家生物技术公司报告本季度每股收益为 0.29 美元，超出分析师共识预期的 0.23 美元，超出幅度为 0.06 美元。Corcept Therapeutics 的净利润率为 19.33%，股本回报率为 20.40%。该公司本季度的收入为 1.9443 亿美元，而分析师预期为 1.9940 亿美元。去年同期，该公司每股收益为 0.32 美元。与去年同期相比，该公司的季度收入增长了 18.7%。平均而言，股票分析师预计 Corcept Therapeutics 今年将发布 1.36 美元的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, CEO Joseph K. Belanoff sold 615 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.69, for a total value of $45,319.35. Following the sale, the chief executive officer directly owned 2,901,370 shares in the company, valued at approximately $213,801,955.30. This trade represents a 0.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 473 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $73.44, for a total transaction of $34,737.12. Following the completion of the transaction, the insider owned 17,705 shares of the company's stock, valued at approximately $1,300,255.20. This trade represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,038 shares of company stock worth $13,237,621 in the last quarter. Corporate insiders own 20.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Joseph K. Belanoff 于 7 月 17 日出售了 615 股公司的股票，交易发生在该日。股票以平均价格 73.69 美元出售，总价值为 45,319.35 美元。出售后，首席执行官直接持有该公司 2,901,370 股股票，估值约为 213,801,955.30 美元。这笔交易代表其持股比例下降了 0.02%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，内部人士 Sean Maduck 于 7 月 18 日出售了 473 股公司的股票，交易发生在该日。股票以平均价格 73.44 美元出售，总交易额为 34,737.12 美元。交易完成后，该内部人士持有 17,705 股公司股票，估值约为 1,300,255.20 美元。这笔交易代表其持股比例下降了 2.60%。该销售的披露信息可以在这里找到。内部人士在上个季度总共出售了价值 13,237,621 美元的 173,038 股公司股票。公司内部人士持有该公司 20.80% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. Brooklyn Investment Group increased its stake in shares of Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 186 shares in the last quarter. MassMutual Private Wealth &amp; Trust FSB increased its stake in Corcept Therapeutics by 102.0% during the 1st quarter. MassMutual Private Wealth &amp; Trust FSB now owns 620 shares of the biotechnology company's stock valued at $71,000 after purchasing an additional 313 shares in the last quarter. Covestor Ltd boosted its holdings in Corcept Therapeutics by 1,741.2% during the first quarter. Covestor Ltd now owns 626 shares of the biotechnology company's stock worth $72,000 after purchasing an additional 592 shares during the last quarter. IFP Advisors Inc boosted its holdings in Corcept Therapeutics by 1,150.8% during the first quarter. IFP Advisors Inc now owns 738 shares of the biotechnology company's stock worth $84,000 after purchasing an additional 679 shares during the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Corcept Therapeutics in the 2nd quarter worth about $56,000. Institutional investors own 93.61% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Brooklyn Investment Group 在第一季度将其在 Corcept Therapeutics 的股份增加了 99.5%。Brooklyn Investment Group 现在拥有 373 股生物技术公司的股票，估值为 43,000 美元，此前在上个季度又增持了 186 股。MassMutual Private Wealth &amp; Trust FSB 在第一季度将其在 Corcept Therapeutics 的股份增加了 102.0%。MassMutual Private Wealth &amp; Trust FSB 现在拥有 620 股生物技术公司的股票，估值为 71,000 美元，此前在上个季度又增持了 313 股。Covestor Ltd 在第一季度将其在 Corcept Therapeutics 的持股增加了 1,741.2%。Covestor Ltd 现在拥有 626 股生物技术公司的股票，价值 72,000 美元，此前在上个季度又增持了 592 股。IFP Advisors Inc 在第一季度将其在 Corcept Therapeutics 的持股增加了 1,150.8%。IFP Advisors Inc 现在拥有 738 股生物技术公司的股票，价值 84,000 美元，此前在上个季度又增持了 679 股。最后，USA Financial Formulas 在第二季度购买了 Corcept Therapeutics 的新股份，价值约为 56,000 美元。机构投资者持有该公司 93.61% 的股份。</p>
</div><h2>Corcept Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Corcept Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.</p>
<div class="lb-trans"><p>Corcept Therapeutics Incorporated 在美国从事用于治疗严重内分泌、肿瘤、代谢和神经系统疾病的药物的发现和开发。它提供 Korlym 片剂，用于治疗因内源性库欣综合症导致的高血糖症，适用于成年患者；以及患有 2 型糖尿病或葡萄糖耐受不良且未能接受手术或不适合手术的患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Corcept Therapeutics</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Rocket Lab Reports Next Week: Here’s What Investors Should Know</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Apple Stock: Big Earnings, Small Move—Time to Buy?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Amazon's Earnings: What Comes Next and How to Play It</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Corcept Therapeutics</li>
<li>现在可以购买的两只金融科技股票和一只需要避免的股票</li>
<li>Rocket Lab 下周报告：投资者需要知道的事项</li>
<li>零售投资者如何交易多伦多证券交易所 (TSX)？</li>
<li>苹果股票：大盈利，小波动——是时候购买了吗？</li>
<li>便士股票适合你的投资组合吗？</li>
<li>亚马逊的盈利：接下来会发生什么以及如何应对</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09SVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CORT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Corcept Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corcept Therapeutics 吗？</h2>
</div><p>Before you consider Corcept Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Corcept Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corcept Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前购买的股票……而 Corcept Therapeutics 并不在名单上。</p>
</div><p>While Corcept Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corcept Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Canaccord Genuity Group 的分析师将 Corcept Therapeutics（纳斯达克股票代码：CORT）的目标股价下调至 137.00 美元